Through our Protein Fingerprint technology, we identify fragments of the Extracellular Matrix (ECM) that are released from affected tissues and develop blood-based biomarker assays to quantify disease activity with the aim of precision medicine.
By quantifying tissue remodeling, our biomarkers provide true prognostic and predictive value, as we can select the patients who are most likely to respond to a given treatment and thereby function as surrogate biomarkers for clinical trials. Our biomarker assays not only enable faster drug development but also improve disease outcomes for chronically ill patients by predicting treatment response.
Watch more videos about Nordic Bioscience's biomarkers and the ECM on our YouTube channel!
How can we help you?
Please don't hesitate to contact us if you have any questions or other inquiries.
